Skip to content

Andrew R. Green

3 papers in the library · 151 citations · publishing 2008-2014

Papers

Sort Most recent Most cited

The preclinical pharmacology of mephedrone; not justMDMAby another name

British Journal of Pharmacology March 24, 2014 Andrew R. Green, Madeleine V. King, Sinead E Shortall et al. 70 citations

The substituted β‐keto amphetamine mephedrone (4‐methylmethcathinone) was banned in the UK in A pril 2010 but continues to be used recreationally in the UK and elsewhere. Users have compared its psychoactive effects to those of 3,4‐methylenedioxymethamphetamine ( MDMA , ‘ecstasy’). This review critically examines the preclinical data on mephedrone that have appeared over the last 2–3 years and,...

Differential effects of cathinone compounds andMDMAon body temperature in the rat, and pharmacological characterization of mephedrone‐induced hypothermia

British Journal of Pharmacology October 8, 2012 Sinead E Shortall, Andrew R. Green, Km Swift et al. 51 citations

Background and Purpose Recreational users report that mephedrone has similar psychoactive effects to 3,4‐methylenedioxymethamphetamine ( MDMA ). MDMA induces well‐characterized changes in body temperature due to complex monoaminergic effects on central thermoregulation, peripheral blood flow and thermogenesis, but there are little preclinical data on the acute effects of mephedrone or other...

Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5‐HT in the UK

British Journal of Pharmacology June 2, 2008 Andrew R. Green 30 citations

The vasoconstrictor substance named serotonin was identified as 5‐hydroxytryptamine (5‐HT) by Maurice Rapport in 1949. In 1951, Rapport gave Gaddum samples of 5‐HT substance allowing him to develop a bioassay to both detect and measure the amine. Gaddum and colleagues rapidly identified 5‐HT in brain and showed that lysergic acid diethylamide (LSD) antagonized its action in peripheral tissues....